Loading…
← CockpitCompetitor Analysis › 002422.SZ Sichuan Kelun Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Sichuan Kelun Pharmaceutical Co., Ltd. Class A002422.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology

Chinese pharma maker of generic drugs and IV infusions, with a biotech arm developing antibody-drug conjugates licensed to Merck.

≈ A generics manufacturer with a Seagen-like ADC biotech unitMomentum leader 94
Mkt cap
$10.1B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$111M
20-day average traded
Fwd P/E
35.6×
forward earnings
ROIC−WACC
+1.6 pp
WACC 5.0%
Hurdle
+4 pp
Req g minus delivered
Next earnings
162 days
29 Apr 2027
Close · CNYCN¥42.29
1D-0.1%
1W-3.3%
1M-2.1%
3M-8.7%
6M+34.8%
YTD+44.1%
1Y+24.5%
ATR %4.6%
52w lowhigh19.9% off high

What Sichuan Kelun Pharmaceutical does

Chinese pharma maker of generic drugs and IV infusions, with a biotech arm developing antibody-drug conjugates licensed to Merck.

Earns most of its income from selling large-volume IV infusions, such as saline and glucose bags, and generics to hospitals, a volume business squeezed by government bulk-buying tenders. Its separately listed subsidiary, Kelun-Biotech, brings licensing and milestone income from Merck for antibody-drug conjugates, drugs that carry a toxin straight to tumor cells.

In one line: A generics manufacturer with a Seagen-like ADC biotech unit.

Products and services

  • Generic drugs
  • IV infusion products
  • Antibody-drug conjugates (Kelun-Biotech)

Customers

  • Hospitals
  • Pharmacies
  • Global pharma licensing partners

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Generic pharma manufacturing plus…

What could go right

  • ADC licensing/milestone payments from Merck

What could go wrong

  • Generic drug price-cut policy (VBP)
  • Clinical trial/regulatory risk on ADCs

Moat: narrow (IP / patents, scale). Large generics/infusion base funds an ADC pipeline validated by a major Merck licensing deal.

Headquarters: Chengdu, China · Founded: 1996 · Employees: 20,127

Named competitors

Sichuan Kelun Pharmaceutical at a glance

Size Sichuan Kelun Pharmaceutical (002422.SZ) is a China Health Care company (Biotechnology) with a market value of $10.1B, the 234th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥42.29 on 18 Nov 2026.

Performance Over six months the shares gained 34.8%, against +23.0% for the median peer and -20.0% for the China market (cap-weighted) — 8th highest of 21 in its peer set.

Growth Revenue grew 0.3% over the last twelve months (peer median +32.0%); the operating margin is 9.4% (peer median 9.9%).

Valuation It trades at 35.6× forward earnings against a peer median of 28.0× (5th most expensive of 11).

Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 1.6 points above its cost of capital (5.0% WACC).

Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).

Relative performance

10012515021 May 202621 Aug 202618 Nov 2026002422.SZ 138Peer median 119
Six months, rebased to 100: Sichuan Kelun Pharmaceutical against the median of its 20 peers (local-currency closes).

Sichuan Kelun Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥18.3BCN¥18.4BCN¥21.6BCN¥21.3BCN¥18.9B
Revenue growth—-15%+2%+13%—
Gross profitCN¥9.60BCN¥8.40BCN¥10.8BCN¥10.8BCN¥9.57B
EBITDAn/aCN¥3.43BCN¥5.14BCN¥4.54BCN¥3.39B
Net incomeCN¥1.97BCN¥1.70BCN¥2.94BCN¥2.46BCN¥1.71B
Free cash flowCN¥2.49BCN¥1.19BCN¥3.02BCN¥3.70BCN¥2.34B
Capital expenditureCN¥1.40BCN¥1.62BCN¥1.68BCN¥1.77BCN¥897M
Total debtCN¥4.33BCN¥4.36BCN¥4.42BCN¥7.56BCN¥11.6B

Quarterly statements and history in the cockpit →

Sichuan Kelun Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-20%0%+20%KYMRHALOKRYSPCVXTECH1961701548BMRN1093SMMTTWSTELANTXGCGONAXSMIMVTBBIOKODNBIX002422.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Sichuan Kelun Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%0×100×200×300×HALOKRYSTECH1961701548BMRN1093ELANAXSMNBIX002422.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Sichuan Kelun Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%HALOKRYSTECH1961701548BMRN1093ELANTXGNBIX002422.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Sichuan Kelun Pharmaceutical is the large dot.

Sichuan Kelun Pharmaceutical competitors and peer comparison

Head to head with its named competitors (002422.SZ vs 600276.SS vs MRK vs 1177.HK)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Sichuan Kelun Pharmaceutical 002422.SZ$10.1B+35%0%9%35.6×6.2%
Jiangsu Hengrui Pharmaceuticals 600276.SS$45.7B-13%+6%27%33.4×13.4%
Merck & MRK$340B+23%+5%18%16.4×8.3%
Sbp 1177.HK$12.2B+5%+15%30%17.5×-5.7%

How Sichuan Kelun Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Sichuan Kelun Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure002422.SZPeer medianRank in peer set
1-month return-2.1%-5.4%10th highest of 21
6-month return+34.8%+23.0%8th highest of 21
Distance from 52-week high-19.9%-26.2%10th highest of 21
Revenue growth (TTM)+0.3%+32.0%3rd lowest of 17
Operating margin9.4%9.9%9th highest of 17
Forward P/E35.6×28.0×5th most expensive of 11
Growth the price implies (Req g, 7 yrs)6.2%18.9%4th least demanding of 11
Growth delivered (Del g)+2.3%+18.2%2nd lowest of 11
Hurdle (Req g minus delivered)+3.8 pp-7.3 pp5th most demanding of 11
ROIC minus cost of capital+1.6 pp-3.6 pp6th highest of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Sichuan Kelun Pharmaceutical 002422.SZChina$10.1B+35%0%9%35.6×6.2%+2.3%
Kymera Therapeutics KYMRUnited States$10.3B+50%+134%-396%n/an/an/a
Halozyme Therapeutics HALOUnited States$10.9B+39%+45%57%9.5×-0.3%+39.2%
Krystal Biotech KRYSUnited States$9.34B+4%+26%48%36.3×13.1%+26.0%
Vaxcyte PCVXUnited States$9.26B+24%n/an/an/an/an/a
Bio-Techne TECHUnited States$11.4B+56%+1%21%34.4×31.6%+5.5%
ALTEOGEN 196170.KSSouth Korea$8.80B-56%+61%53%42.0×24.6%+38.5%
Genscript Biotech 1548.HKHong Kong$8.69B+133%+53%12%294.1×36.9%+19.8%
BioMarin Pharmaceutical BMRNUnited States$11.9B+22%+20%19%11.2×8.2%+12.0%
Cspc Pharma 1093.HKHong Kong$12.0B+10%+25%28%9.1×-10.7%+0.1%
Summit Therapeutics SMMTUnited States$8.40B-41%n/an/an/an/an/a
Twist Bioscience TWSTUnited States$7.93B+117%+22%-29%n/an/an/a
Elanco Animal Health ELANUnited States$13.3B+28%+12%8%21.5×32.9%+7.6%
10x Genomics TXGUnited States$7.51B+138%-4%-11%n/a47.2%+16.6%
CG Oncology CGONUnited States$7.15B+24%+184%-4,294%n/an/an/a
Axsome Therapeutics AXSMUnited States$7.05B-42%+54%-19%77.1×n/an/a
Immunovant IMVTUnited States$6.86B-7%n/an/an/an/an/a
BridgeBio Pharma BBIOUnited States$15.2B+14%+167%-37%n/an/an/a
Kodiak Sciences KODUnited States$6.40B+170%n/an/an/an/an/a
Neurocrine Biosciences NBIXUnited States$16.5B+5%+38%25%18.0×-1.5%+22.3%
Arrowhead Pharmaceuticals ARWRUnited States$6.09B-44%-46%-157%n/an/an/a

Questions

Who are Sichuan Kelun Pharmaceutical's main competitors?
Named competitors: Hengrui Medicine (600276.SS), Merck & Co. (MRK), Sino Biopharmaceutical (1177.HK). The cockpit's measured peer set (industry) also includes Kymera Therapeutics (KYMR), Halozyme Therapeutics (HALO), Krystal Biotech (KRYS), Vaxcyte (PCVX), Bio-Techne (TECH), ALTEOGEN (196170.KS).
Is Sichuan Kelun Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 35.6× against a peer median of 28.0×, 5th most expensive of 11 in its peer set. For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Sichuan Kelun Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned +34.8% against +23.0% for the median peer; over one year +24.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.